95 related articles for article (PubMed ID: 15242684)
1. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
3. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
4. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
5. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
6. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
7. Expression, purification, and inhibition of human RET tyrosine kinase.
Mologni L; Sala E; Riva B; Cesaro L; Cazzaniga S; Redaelli S; Marin O; Pasquato N; Donella-Deana A; Gambacorti-Passerini C
Protein Expr Purif; 2005 May; 41(1):177-85. PubMed ID: 15802236
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M; Pützer BM
Nat Clin Pract Oncol; 2006 Oct; 3(10):564-74. PubMed ID: 17019434
[TBL] [Abstract][Full Text] [Related]
9. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of the RET receptor in human cancer.
Santoro M; Carlomagno F; Melillo RM; Fusco A
Cell Mol Life Sci; 2004 Dec; 61(23):2954-64. PubMed ID: 15583857
[TBL] [Abstract][Full Text] [Related]
11. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
12. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
13. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
14. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
16. RET TKI: potential role in thyroid cancers.
Antonelli A; Fallahi P; Ferrari SM; Mancusi C; Colaci M; Santarpia L; Ferri C
Curr Oncol Rep; 2012 Apr; 14(2):97-104. PubMed ID: 22286373
[TBL] [Abstract][Full Text] [Related]
17. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Bowles DW; Kessler ER; Jimeno A
Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.
Ding S; Wang R; Peng S; Luo X; Zhong L; Yang H; Ma Y; Chen S; Wang W
Biomed Pharmacother; 2020 Dec; 132():110901. PubMed ID: 33125973
[TBL] [Abstract][Full Text] [Related]
19. New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?
Birner P; Bartsch R; Schreiber M; Dubsky P; Kenner L
Future Oncol; 2014 Feb; 10(3):333-6. PubMed ID: 24559440
[No Abstract] [Full Text] [Related]
20. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
